| Jun 1 |
Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
|
| May 31 |
Immunocore touts updated phase 1 results for melanoma asset brenetafusp
|
| May 31 |
Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
|
| May 30 |
Immunocore to present at the Jefferies Global Healthcare Conference
|
| May 29 |
Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
|
| May 24 |
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
|
